Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cencora, Inc. (NYSE: COR) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large pharmaceutical solutions and distribution organization, Cencora uses its SEC reports to present detailed information about its financial performance, capital structure, governance, and significant transactions.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand Cencora’s revenue composition, segment performance for U.S. Healthcare Solutions and International Healthcare Solutions, and the impact of acquisitions such as Retina Consultants of America. These filings also describe non-GAAP measures like adjusted operating income and adjusted diluted earnings per share, along with reconciliations to GAAP metrics.
Cencora’s Form 8-K current reports offer timely updates on material events, including amendments to credit facilities, changes to its receivables securitization program, issuance and listing of senior notes, revisions to its reporting structure, and agreements to acquire additional equity interests in OneOncology. Other 8-Ks disclose governance developments, such as board appointments and leadership changes, as well as information about legal settlements and derivative actions.
Through Stock Titan, users can also track registered debt securities like Cencora’s 2.875% Senior Notes due 2028 (COR28) and 3.625% Senior Notes due 2032 (COR32), which are listed alongside the common stock. Where available, insider transaction reports on Forms 3, 4, and 5 can help users monitor equity ownership changes by directors and officers.
AI-powered tools on the platform summarize lengthy Cencora filings, highlight key changes from prior periods, and surface important disclosures about liquidity, financing arrangements, segment realignments, and legal matters. This helps readers quickly interpret complex documents and focus on the sections most relevant to their analysis of COR.
Cencora (NYSE:COR) filed a Form 4 reporting insider transactions by Executive Chairman Steven H. Collis on 24 June 2025.
Collis exercised 12,579 stock options at an exercise price of $86.09 (code M) and sold 14,579 common shares at an average price of $292.62 (code S) under a pre-arranged Rule 10b5-1 trading plan adopted 25 Nov 2024. The sale is valued at roughly $4.3 million.
Following the transactions he directly owns 311,912.665 shares of common stock and retains 113,206 outstanding options. The disposition represents about 4.7 % of his prior direct holdings, yet he continues to hold a substantial equity stake.
Cencora, Inc. (Form 144) – A notice of proposed insider sale has been filed for 14,579 common shares with an estimated aggregate market value of $4,266,106.98. The sale is expected to be executed on 06/24/2025 through Fidelity Brokerage Services on the NYSE.
The filing discloses that Cencora has 193,823,487 shares outstanding; the planned transaction therefore represents roughly 0.0075 % of the company’s total shares, indicating an immaterial effect on share count but providing insight into insider behavior.
Acquisition background:
- 2,000 shares acquired via restricted-stock vesting on 09/30/2023 (compensation).
- 12,579 shares acquired via option exercise dated 06/24/2025 (cash payment).
Recent insider activity (past three months):
- 03/25/2025 – 14,578 shares sold for $3,928,916.78
- 04/22/2025 – 14,579 shares sold for $4,108,507.99
- 05/20/2025 – 14,578 shares sold for $4,283,599.52
No relationship to the issuer is specified in the excerpt, and no Rule 10b5-1 plan adoption date is provided. The filer certifies that no undisclosed material adverse information is known at the time of filing.
Cencora, Inc. (COR) – Form 4 insider transaction
Executive Vice President Silvana Battaglia reported the sale of 4,077 common shares on 18-Jun-2025 at an average price of $297.405 per share. Following the transaction, Battaglia’s direct holding stands at 11,296.889 shares. No derivative securities were involved, and no Rule 10b5-1 plan was indicated. The filing was signed on 20-Jun-2025.